WO2025141483 - METHOD FOR MODULATING AFUCOSYLATION LEVEL OF PERTUZUMAB
National phase entry is expected:
Publication Number
WO/2025/141483
Publication Date
03.07.2025
International Application No.
PCT/IB2024/063164
International Filing Date
25.12.2024
Title **
[English]
METHOD FOR MODULATING AFUCOSYLATION LEVEL OF PERTUZUMAB
[French]
PROCÉDÉ DE MODULATION DU NIVEAU DE DÉFUCOSYLATION DU PERTUZUMAB
Applicants **
INTAS PHARMACEUTICALS LTD.
Inventors
ADHIKARY, Laxmi
MAHALINGAM, Velu
SHAH, Kinchit
PATEL, Hiral S.
MISHRA, Surbhi
SINGH, Varsha
PALSOKAR, Mrunal
SETH, Mrinal
Priority Data
202321089627
29.12.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1955 | |
| EPO | Filing, Examination, Granting | 11624 | |
| Japan | Filing, Examination, Granting | 1952 | |
| South Korea | Filing, Examination, Granting | 1659 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
22,530
Contact Us
Abstract[English]
cells/mL.[French]
La présente invention concerne un procédé de modulation du niveau de défucosylation du pertuzumab, à l'aide d'un changement du pH de milieux de culture cellulaire, lorsque la culture cellulaire atteint le nombre de (18-22) x 106 cellules viables/mL.